SCIENCE

The NOVVA™ Platform

NOVVA™ (Nanocomplex Optimized Vehicle Vectored by Antibody) is Lumigen's proprietary platform for precision cancer drug delivery. By combining the selectivity of targeted antibodies with advanced nanoparticle engineering, NOVVA™ is designed to improve how cancer therapies reach and penetrate solid tumors while reducing off-target exposure.

Because the platform is modular, NOVVA™ can be adapted to pair different therapeutic payloads with validated cancer targets, creating a scalable pipeline of targeted oncology medicines.

    
        Comparison of NOVVA, targeted biologics, and conventional chemotherapy
        across selected targeting and drug-delivery characteristics.
      
          NOVVA™
          Targeted Biologics
          Conventional Chemotherapy
        
          Precision targeting

          Engineered for intratumoral distribution

          Delivers an encapsulated therapeutic payload

          Designed to minimize off-target exposure

Publications

A selection of key resources and publications about our pipeline.

➤ Preclinical proof of concept in triple negative breast cancer

➤ Preclinical proof of concept for targeted delivery in glioblastoma

➤ Targeted nanoparticle penetration in glioblastoma

➤ Low-adhesion nanoparticles can solve delivery barrier to reach glioblastoma cells

➤ Fn14 as a therapeutic target across aggressive solid tumors